


IFW



Atty. Docket No.: 17633/2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Woolf, et. al.
Serial No.: 10/743,643
Filed: December 22, 2003
Entitled: Nucleic Acid and Amino Acid
Sequences Involved in Pain

Examiner: Not Yet Assigned
Group Art Unit: Not Yet Assigned
Conf. No.: Not Yet Assigned

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Nancy Arsenault

Name of Person Mailing Paper

Signature of Person Mailing Paper

**Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450**

TRANSMITTAL LETTER

Enclosed for filing in the above-identified patent application, please find the following documents:

1. Information Disclosure Statement;
2. Form PTO-1449; and
3. Return Post Card.

The Commissioner for Patents is hereby authorized to charge any fees to Deposit Account No. 16-0085, Reference 17633/2005. A duplicate of this transmittal letter is enclosed for this purpose.

Respectfully submitted,

Date: 8/17/04

Name: Matthew Beaudet

Registration No.: 50,649

Customer No.: 29933

Palmer & Dodge LLP

111 Huntington Avenue

Boston, MA 02199-7613

Tel: 617-239-0100



Atty. Docket No.: 17633/2005

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Woolf, et. al.
Serial No.: 10/743,643
Filed: December 22, 2003
Entitled: Nucleic Acid and Amino Acid
Sequences Involved in Pain

Examiner: Not Yet Assigned

Group Art Unit:

Conf. No.:

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8a

I hereby certify that this correspondence (and any paper or fee referred to as being enclosed) is being deposited with the United States Post Office as First Class Mail on the date indicated below in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Nancy Arsenault

Name of Person Mailing Paper

Signature of Person Mailing Paper

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §§ 1.56, 1.97 AND 1.98**

Dear Sir:

In accordance with the duty of disclosure under 37 CFR § 1.56, Applicant submits this Information Disclosure Statement pursuant to 37 CFR §§ 1.97 and 1.98 in the above-identified application for consideration by the Patent Office.

A copy of the cited documents were submitted to the U.S. Patent and Trademark Office in the parent application, U.S. Serial No. 10/219,051. Pursuant to CFR § 1.97(b)(3), because this Statement is being submitted before the first Office Action on the merits, no fee is required.


Applicant does not intend to represent that any of the documents submitted herein are material prior art to this invention or that the list represents an exhaustive search of documents related to this invention.

Applicant respectfully requests that the documents submitted herein be considered and made of record in this application.

Date: 8/17/04

Respectfully submitted,

Name: Matthew Beaudet
Registration No.: 50,649
Customer No.: 29933
Palmer & Dodge LLP
111 Huntington Avenue
Boston, MA 02199-7613
Tel: 617-239-0100



USPTO Form 1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE STATEMENT				Attorney Docket No. 17633/2005		Serial No. 10/743,643		
				Applicant(s): Woolf, et al				
				Filing Date: December 22, 2003		Group: Not Yet Assigned		
U.S. PATENT DOCUMENTS								
Examiner Initial		Patent No.	Date	Name	Class	Subclass	Filing Date (if appropriate)	
FOREIGN PATENT DOCUMENTS								
Examiner Initial		Document No.	Publication Date	Country	Class	Subclass	Translation	
							YES	NO
OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)								
	1.	McCleskey and Gold, <i>Ion Channels of Nociception</i> , 1999, <i>Annu. Rev. Physiol.</i> 61: 835-856.						
	2.	Mogil et al., <i>Pain Genes?: Natural Variation and Transgenic Mutants</i> , 2000, <i>Annu. Rev. Neurosci.</i> 23: 777-811.						
	3.	Sindrup and Jensen, <i>Efficacy of Pharmacological Treatments of Neuropathic Pain: An Update and Effect Related to Mechanism of Drug Action</i> , 1999 <i>Pain</i> 83: 389-400.						
	4.	Woolf and Decosterd, <i>Implications of Recent Advances in the Understanding of Pain Pathophysiology for the Assessment of Pain in Patients</i> , 1999, <i>Pain</i> 6: S141-S147.						
	5.	Woolf and Mannion, <i>Neuropathic Pain: Aetiology, Symptoms, Mechanisms and Management</i> , 1999, <i>Lancet</i> 353: 1959 – 1964.						
	6.	Woolf and Salter, <i>Neuronal Plasticity: Increasing the Gain in Pain</i> , 2000, <i>Science</i> 288: 1765-1768.						
EXAMINER					DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.								
**Copies of references not provided at the time of this submission.								